ATM and neoplasm: Further stratification of models by truncating ATM mutations (n = 8; all tATM IHC H score low) showed that AZD6738 monotherapy achieved a minimum of 50% TGI best response in three (GA2254, OV2029, and PA3023) of five models with a VAF >0.5 (60%) (Figure 3a–c and Figure 4a for tumour growth curves) and in none of the three models with a VAF ≤ 0.5 (0%) (Figure 3a and Figure 4b for tumour growth curves).